These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

319 related articles for article (PubMed ID: 38196523)

  • 1. Efficacy and safety of regorafenib in combination with immune checkpoint inhibitor therapy as second-line and third-line regimen for patients with advanced hepatocellular carcinoma: a retrospective study.
    Zhao J; Guo Y; Feng T; Rong D; Kong X; Huang T; Lopez-Lopez V; Yarmohammadi H; Sakamoto Y; Zhu D; Yao A; Xia Y
    J Gastrointest Oncol; 2023 Dec; 14(6):2549-2558. PubMed ID: 38196523
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A multi-center retrospective study on the efficacy and safety of regorafenib
    Yan T; Huang C; Peng C; Duan X; Ji D; Duan Y; Zhang W; Zhao H; Gao K; Yang X; Zhang L; Cheng J; de Castria TB; Pocha C; Tsilimigras DI; Wu T; Su G; Li Y; Yu L; Lu Y
    Ann Transl Med; 2023 Jan; 11(2):109. PubMed ID: 36819518
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy and Safety of Regorafenib Combined with Toripalimab in the Third-Line and beyond Treatment of Advanced Colorectal Cancer.
    Yu W; Tao Q; Zhang Y; Yi F; Feng L
    J Oncol; 2021; 2021():9959946. PubMed ID: 34603452
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Single or combined immune checkpoint inhibitors compared to first-line platinum-based chemotherapy with or without bevacizumab for people with advanced non-small cell lung cancer.
    Ferrara R; Imbimbo M; Malouf R; Paget-Bailly S; Calais F; Marchal C; Westeel V
    Cochrane Database Syst Rev; 2020 Dec; 12(12):CD013257. PubMed ID: 33316104
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical Efficacy and Safety of an Immune Checkpoint Inhibitor in Combination with Regorafenib Therapy as Second-Line Regimen for Patients with Unresectable Hepatocellular Carcinoma.
    Li J; Jia Y; Shao C; Li Y; Song J
    Ther Clin Risk Manag; 2023; 19():329-339. PubMed ID: 37041973
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Study on safety and efficacy of regorafenib combined with transcatheter arterial chemoembolization in the treatment of advanced hepatocellular carcinoma after first-line targeted therapy.
    Wang H; Xiao W; Han Y; Cao S; Zhang Z; Chen G; Hu Y; Jin L
    J Gastrointest Oncol; 2022 Jun; 13(3):1248-1254. PubMed ID: 35837179
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy and safety of regorafenib as a first-line agent alone or in combination with an immune checkpoint inhibitor for advanced hepatocellular carcinoma: a retrospective cohort study.
    Yu J; Bai Y; Cui Z; Cheng C; Ladekarl M; Cheng KC; Chan KS; Yarmohammadi H; Mauriz JL; Zhang Y
    J Gastrointest Oncol; 2024 Jun; 15(3):1072-1081. PubMed ID: 38989425
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immune checkpoint inhibitors and anti-vascular endothelial growth factor antibody/tyrosine kinase inhibitors with or without transarterial chemoembolization as first-line treatment for advanced hepatocellular carcinoma (CHANCE2201): a target trial emulation study.
    Jin ZC; Chen JJ; Zhu XL; Duan XH; Xin YJ; Zhong BY; Chen JZ; Tie J; Zhu KS; Zhang L; Huang M; Piao MJ; Li X; Shi HB; Liu RB; Xu AB; Ji F; Wu JB; Shao GL; Li HL; Huang MS; Peng ZY; Ji JS; Yuan CW; Liu XF; Hu ZC; Yang WZ; Yin GW; Huang JH; Ge NJ; Qi X; Zhao Y; Zhou JW; Xu GH; Tu Q; Lin HL; Zhang YJ; Jiang H; Shao HB; Su YJ; Chen TS; Shi BQ; Zhou X; Zhao HT; Zhu HD; Ren ZG; Teng GJ;
    EClinicalMedicine; 2024 Jun; 72():102622. PubMed ID: 38745965
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy and safety of anti-PD-1 monotherapy
    Liu Q; Li R; Li L; Wang G; Ji S; Zheng X; Jia X; Tao H; Hu Y
    Ther Adv Med Oncol; 2023; 15():17588359231206274. PubMed ID: 37885459
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and Safety of Regorafenib Plus Immune Checkpoint Inhibitors with or Without TACE as a Second-Line Treatment for Advanced Hepatocellular Carcinoma: A Propensity Score Matching Analysis.
    Yang X; Deng H; Sun Y; Zhang Y; Lu Y; Xu G; Huang X
    J Hepatocell Carcinoma; 2023; 10():303-313. PubMed ID: 36874252
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Chidamide plus Tyrosine Kinase Inhibitor Remodel the Tumor Immune Microenvironment and Reduce Tumor Progression When Combined with Immune Checkpoint Inhibitor in Naïve and Anti-PD-1 Resistant CT26-Bearing Mice.
    Chen JS; Hsieh YC; Chou CH; Wu YH; Yang MH; Chu SH; Chao YS; Chen CN
    Int J Mol Sci; 2022 Sep; 23(18):. PubMed ID: 36142591
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and Safety of PD-1/PD-L1 Inhibitors in Advanced Hepatocellular Carcinoma: A Systematic Review and Meta-analysis.
    Liu Y; Pan J; Gao F; Xu W; Li H; Qi X
    Adv Ther; 2023 Feb; 40(2):521-549. PubMed ID: 36399316
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Lenvatinib plus anti-PD-1 antibodies as conversion therapy for patients with unresectable intermediate-advanced hepatocellular carcinoma: a single-arm, phase II trial.
    Zhang W; Tong S; Hu B; Wan T; Tang H; Zhao F; Jiao T; Li J; Zhang Z; Cai J; Ye H; Wang Z; Chen S; Wang Y; Li X; Wang F; Cao J; Tian L; Zhao X; Chen M; Wang H; Cai S; Hu M; Bai Y; Lu S
    J Immunother Cancer; 2023 Sep; 11(9):. PubMed ID: 37730273
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of efficacy and safety between PD-1 inhibitors and PD-L1 inhibitors plus platinum-etoposide as first-line treatment for extensive-stage small-cell lung cancer: a multicenter, real-world analysis.
    Wang Y; Li L; Hu J; Zhao Y; Yan H; Gao M; Yang X; Zhang X; Ma J; Dai G
    BMC Cancer; 2023 Dec; 23(1):1196. PubMed ID: 38057736
    [TBL] [Abstract][Full Text] [Related]  

  • 15. PD-1 inhibitors plus lenvatinib versus PD-1 inhibitors plus regorafenib in patients with advanced hepatocellular carcinoma after failure of sorafenib.
    Xu Y; Fu S; Shang K; Zeng J; Mao Y
    Front Oncol; 2022; 12():958869. PubMed ID: 36176403
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy and safety of immune checkpoint inhibitors for advanced non-small cell lung cancer with or without PD-L1 selection: A systematic review and network meta-analysis.
    Li Y; Liang X; Li H; Chen X
    Chin Med J (Engl); 2023 Sep; 136(18):2156-2165. PubMed ID: 37596898
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparative Efficacy of Cabozantinib and Regorafenib for Advanced Hepatocellular Carcinoma.
    Kelley RK; Mollon P; Blanc JF; Daniele B; Yau T; Cheng AL; Valcheva V; Marteau F; Guerra I; Abou-Alfa GK
    Adv Ther; 2020 Jun; 37(6):2678-2695. PubMed ID: 32424805
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy and safety of transarterial chemoembolization plus antiangiogenic- targeted therapy and immune checkpoint inhibitors for unresectable hepatocellular carcinoma with portal vein tumor thrombus in the real world.
    Feng JK; Liu ZH; Fu ZG; Chai ZT; Sun JX; Wang K; Cheng YQ; Zhu HF; Xiang YJ; Zhou LP; Shi J; Guo WX; Zhai J; Cheng SQ
    Front Oncol; 2022; 12():954203. PubMed ID: 36505818
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Regorafenib combined with a PD-1 inhibitor in the second-line setting for unresectable hepatocellular carcinoma in real-world practice.
    Bi H; Pei J; Ma K; Zhang Y; Aprile G; Moris D; Méndez-Sánchez N; Samant H; Sun X; Xia F
    J Gastrointest Oncol; 2024 Feb; 15(1):368-376. PubMed ID: 38482245
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Lenvatinib Plus Programmed Cell Death Protein-1 Inhibitor Beyond First-Line Systemic Therapy in Refractory Advanced Biliary Tract Cancer: A Real-World Retrospective Study in China.
    Shi C; Li Y; Yang C; Qiao L; Tang L; Zheng Y; Chen X; Qian Y; Yang J; Wu D; Xie F
    Front Immunol; 2022; 13():946861. PubMed ID: 35967452
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.